ProfileGDS5678 / 1431081_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 77% 78% 78% 78% 79% 80% 78% 77% 78% 79% 78% 78% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.247977
GSM967853U87-EV human glioblastoma xenograft - Control 25.3183577
GSM967854U87-EV human glioblastoma xenograft - Control 35.3483578
GSM967855U87-EV human glioblastoma xenograft - Control 45.5113278
GSM967856U87-EV human glioblastoma xenograft - Control 55.3672178
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3041279
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5201480
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3104278
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3144777
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4010178
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5327479
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4091178
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3262578
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3385778